Accelerate Diagnostics Names Tom Brown to Board of Directors
March 15 2017 - 12:15PM
Accelerate Diagnostics, Inc. today announced the election of Tom
Brown to the company’s board of directors. His appointment is
effective March 14, 2017.
Brown’s appointment adds over 30 years of medical
diagnostics expertise to the company’s board of directors.
Beginning his career with the Abbott Laboratories Diagnostics
Division (ADD) in 1974, Brown held numerous sales, marketing and
general management positions of increasing responsibility. He
served in positions including Divisional Vice President of Sales
within the United States, and Divisional Vice President and General
Manager of the Western Hemisphere, and by 1993 he was Corporate
Vice President of Worldwide Diagnostic Commercial Operations. He
was named Senior Vice President before becoming President of the
Diagnostic Division, the role he served until his retirement in
2002.
“Tom is a proven leader with a wealth of experience
in the diagnostics industry,” said Chairman of the Board, John
Patience. “His extensive background, particularly in launching and
commercializing new diagnostic solutions, will be increasingly
valuable as the company launches the Accelerate Pheno™ system and
introduces additional novel solutions to the microbiology
laboratory.”
Tom Brown currently serves on the board of
directors of Quidel Corporation and Stericycle, Inc. and has
previously served on the boards of Cepheid, Inc. and Ventana
Medical Systems, Inc. He received a Bachelor of Arts degree
from the State University of New York at Buffalo.
About Accelerate Diagnostics,
Inc.
Accelerate Diagnostics, Inc. (“Accelerate
Diagnostics”), (Nasdaq:AXDX), is an in vitro diagnostics company
dedicated to providing solutions for the global challenge of
antibiotic resistance and healthcare-associated infections. The
company's fully automated Accelerate Pheno™ system, and direct from
positive blood culture Accelerate PhenoTest™ BC kit, leverage a
suite of technologies to eliminate the lengthy culture and sample
preparation steps required prior to testing. Using proprietary
molecular identification methods and morphokinetic cellular
analysis (MCA), the solution aims to reduce the time that
clinicians must wait for quantitative antimicrobial susceptibility
results necessary for optimal antibiotic selection, dosing, and
infusion strategy, called minimum inhibitory concentrations, or
MICs.
The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO”
and “ACCELERATE PHENOTEST” logos and marks are trademarks or
registered trademarks of Accelerate Diagnostics, Inc.
For more information about the company, its
products or technology, visit axdx.com.
Forward-Looking Statements
Certain of the statements made in this press
release are forward looking, such as those related to the
contributions expected to be made by members of the company’s
board. Actual results or developments may differ materially from
those projected or implied in these forward-looking statements.
Information about the risks and uncertainties faced by Accelerate
Diagnostics is contained in the section captioned “Risk Factors” in
the company's most recent Annual Report on Form 10-K, filed with
the Securities and Exchange Commission on February 28, 2017, and in
any other reports that we file with the Securities and Exchange
Commission from time to time. The company's forward-looking
statements could be affected by general industry and market
conditions. Except as required by federal securities laws, the
company undertakes no obligation to update or revise these
forward-looking statements to reflect new events, uncertainties or
other contingencies.
Investors May Contact:
Laura Pierson, Accelerate Diagnostics, +1 520 365-3100
investors@axdx.com
Reporters May Contact:
Andrew Chasteen, Accelerate Diagnostics, +1 520 365-3100
achasteen@axdx.com
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Apr 2023 to Apr 2024